← Human Trials & Peer-Reviewed Studies
Transdermal nicotine-induced tobacco abstinence symptom suppression: nicotine dose and smokers' gender
Plain-language guide to PMID 16756416 (2006): double-blind randomized controlled trial study of Therapeutic nicotine (patch, non-peptide) in 75 men.
Key Facts
- PMID
- 16756416
- Journal
- Experimental and clinical psychopharmacology
- Year
- 2006
- Study type
- Randomized Controlled Trial
- Authors
- Evans SE et al. (5 authors)
- DOI
- 10.1037/1064-1297.14.2.121
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.
An aversive tobacco abstinence syndrome, thought to reflect an underlying level of nicotine dependence, contributes to cigarette smokers' failed quit attempts.
Each session included blood sampling for plasma nicotine level, measurement of heart rate, participants' ratings of tobacco abstinence symptoms and effects of nicotine, and psychomotor performance.
Who Took Part
According to the abstract, 75 men were involved.
The age groups tagged for this paper are adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized and double-blind study.
Because people in this Therapeutic nicotine (patch, non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
Neither the men nor the staff measuring them knew who was on Therapeutic nicotine (patch, non-peptide), so expectations could not easily colour the readings.
What Was Measured
An aversive tobacco abstinence syndrome, thought to reflect an underlying level of nicotine dependence, contributes to cigarette smokers' failed quit attempts.
Each session included blood sampling for plasma nicotine level, measurement of heart rate, participants' ratings of tobacco abstinence symptoms and effects of nicotine, and psychomotor performance.
The subject headings attached to it are Administration, Cutaneous, Heart Rate, Nicotine, Sex Characteristics, Substance Withdrawal Syndrome and Tobacco Use Disorder.
What This Means in Plain Language
The paper is a randomized and double-blind study of Therapeutic nicotine (patch, non-peptide) in 75 men.
The publication is from 2006 (Experimental and clinical psychopharmacology), a journal based in United States.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.